Skip to Content

Embecta Corp.

Securities Class Action

  • Date:
  • 8/18/2026
  • Company Name:
  • Embecta Corp.
  • Stock Symbol:
  • EMBC
  • Class Period:
  • FROM 11/25/2025 TO 5/4/2026
  • Status:
  • Filed
  • Filing Date:
  • 6/17/2026

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Embecta common stock between November 25, 2025 to May 4, 2026, both dates inclusive (the “Class Period”). Investors have until August 17, 2026  to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Embecta’s fiscal results; pertinently, Embecta knew or recklessly disregarded that the Company’s guidance was misleading and unattainable. In fact, Embecta touted the Company’s pen needle business as “incredibly resolute” mere weeks prior to missing expectations and cutting 2026 fiscal guidance.

On May 5, 2026, the Company reported second quarter 2026 earnings, which announced results below analyst expectations and included a reduction to full-year 2026 guidance. The Company stated that the two largest contributors to the results were a “loss within our pen needle product category, most of which is concentrated at a single customer” and “overall market volume softness for insulin pens and pen needles in the retail channel.” As a result of this, the Company also announced “a review of our cost structure and organizational footprint.” On this news, the price of Embecta shares declined by $5.35 per share, or approximately 58%, from $9.25 per share on May 4, 2026 to close at $3.90 on May 5, 2026.

If you purchased or otherwise acquired Embecta shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Embecta Corp.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: